Intravenous immunoglobulins for the treatment of infections in patients with haematological cancers

  • Protocol
  • Intervention

Authors

  • In Sook Friis,

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Matthias Kochanek,

    1. University Hospital of Cologne, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Ina Monsef,

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Nicole Skoetz,

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Andreas Engert,

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Kathrin Bauer

    Corresponding author
    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    • Kathrin Bauer, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, Cologne, 50924, Germany. kathrin.bauer@uk-koeln.de.

    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

We will evaluate the efficacy of intravenous immunoglobulin (IVIG) in the treatment of infections in patients with haematological malignancies with respect to the duration of infections, study mortality, infection-related mortality, adverse events, infection and duration of hospitalisation.